A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free.

Trial Profile

A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Sarcoma-vaccine (Primary) ; OPT 821
  • Indications Sarcoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 14 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 08 Mar 2016 Planned End Date changed from 1 Jun 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 03 Jun 2014 Primary endpoint 'Progression-free-survival-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top